Sweden
· Delayed Price · Currency is SEK SenzaGen AB Company Description
SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity.
The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials.
It also provides irritation, corrosion, sensitization, and absorption testing services, as well as phototoxicity services.
The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization.
The company was incorporated in 2010 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 2010 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Peter Nahlstedt |
Contact Details
Address: Building 401 Lund, 223 81 Sweden | |
| Phone | 46 4 62 75 62 00 |
| Website | senzagen.com |
Stock Details
| Ticker Symbol | SENZA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010219626 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Nahlstedt | President and Chief Executive Officer |
| Marianne Olsson | Vice President of Finance |
| Dr. Henrik Johansson | Chief Scientist |
| Tina Dackemark Lawesson | Vice President of Marketing and Communications |
| Andy Forreryd | Vice President of Sales |
| Helen Olsson | Vice President of Human Resources |